J Korean Cancer Assoc.
2000 Feb;32(1):200-209.
Tumor - specific Virus Replication and Cytotoxicity
of E1B 55 kD - deleted Adenovirus
- Affiliations
-
- 1Departments of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- 2Departments of Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
- 3Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea.
Abstract
-
PURPOSE: To overcome the limitations of cancer gene therapy
using replication-incom- petent adenovirus, we generated E1B
55 kD-deleted adenovirus (YKL-1) by polymerase chain reaction
(PCR) and homologous recombination. We then investigated
tumor-specific virus replication and cytotoxicity of YKL-1
in vitro and in vivo.
MATERIALS AND METHODS
YKL-1 was constructed by reintroducting
E1A and E1B 19 kD into pTG-CMV El/E3-deficient adenoviral vector
and inducing homologous recombination in E. coli. The recombinant
vector pYKL-1 was transfected into 293 cells to generate YKL-1.
The properties of newly constructed YKL-1 was defined by PCR and
immuno- blotting analysis. Virus replication was examined by
infecting human normal and cancer cells on 6-wells at multiplicity
of infection (MOI) of 10 for 3 days. Virus was then recovered and
titered. Cytopathic effect was analyzed by infecting human normal
and cancer cells on 24-wells at MOIs of 10, 1 or 0.1 for 7 to 10
days and staining them with crystal violet solution. Inhibition of
tumor growth was examined in human cancer cell xenografts in nu/nu
mice by intratumoral injection of YKL-l.
RESULTS
PCR and immunoblotting analysis confirmed that YKL-1
contained E1A and E1B 19 kD but not E1B 55 kD. In human normal cells,
virus replication and subsequent cytopathic effect of E1B 55 kD-deleted
adenovirus YKL-1 was markedly attenuated by larger than 2 to 3 log
in magnitude, compared to that of wild-type ad-XJ. In contrast, YKL-1 was
capable of replicating and inducing cytotoxicity i.n most human cancer cells.
C33A and Hep3B containing p53 mutation were much more sensitive, whereas
HeLa and H460 with wild type p53 were relatively resistant to YKL-1.
Finally, the tumor growth was dramatically retarded by intratumoral
injection of YKL-1 in C33A cervical cancer xenograft and the histology
showed significant necrosis by intratumoral injection of YKL-1.
CONCLUSION
The results here demonstrated the ability of preferential
virus replication and cytotoxicity of ElB 55 kD-deleted adenovirus YKL-1
in human cancer cells. Therefore, these indicated a promising potential
of YKL-1 as an antitumoral virus agent and a selective replication-competent
virus vector.